| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Assessing Pathologic Response in Resected Lung Cancers: Current Standards, Proposal for a Novel Pathologic Response Calculator Tool, and Challenges in Practice
|
Saqi, Anjali
|
|
|
3 |
5 |
p.
|
article
|
| 2 |
Autoimmune Disease in Patients With Advanced Thymic Epithelial Tumors
|
Singhal, Surbhi
|
|
|
3 |
5 |
p.
|
article
|
| 3 |
Camrelizumab Plus Apatinib in Treatment-Naive Patients With Advanced Nonsquamous NSCLC: A Multicenter, Open-Label, Single-Arm, Phase 2 Trial
|
Ren, Shengxiang
|
|
|
3 |
5 |
p.
|
article
|
| 4 |
Clinical Outcomes With Dabrafenib Plus Trametinib in a Clinical Trial Versus Real-World Standard of Care in Patients With BRAF-Mutated Advanced NSCLC
|
Johnson, Bruce E.
|
|
|
3 |
5 |
p.
|
article
|
| 5 |
Comparison of 2-Weekly Versus 4-Weekly Durvalumab Consolidation for Locally Advanced NSCLC Treated With Chemoradiotherapy: A Brief Report
|
Denault, Marie-Hélène
|
|
|
3 |
5 |
p.
|
article
|
| 6 |
Complete Remission After Immunotherapy-Induced Abdominal Tuberculosis in a Patient With Advanced NSCLC Treated With Pembrolizumab: A Case Report
|
Riudavets, Mariona
|
|
|
3 |
5 |
p.
|
article
|
| 7 |
Creation of an Integrated Clinical Trial Database and Data Sharing for Conducting New Research by the Japan Lung Cancer Society
|
Ozawa, Yuichi
|
|
|
3 |
5 |
p.
|
article
|
| 8 |
De Novo KRAS G12C–Mutant SCLC: A Case Report
|
Balbach, Meridith L.
|
|
|
3 |
5 |
p.
|
article
|
| 9 |
Efficacy of Adjuvant Chemotherapy With Tegafur-Uracil in Patients With Completely Resected, Node-Negative NSCLC—Real-World Data in the Era of Molecularly Targeted Agents and Immunotherapy
|
Shukuya, Takehito
|
|
|
3 |
5 |
p.
|
article
|
| 10 |
Implementing Lung Cancer Screening in Europe: Taking a Systems Approach
|
Wait, Suzanne
|
|
|
3 |
5 |
p.
|
article
|
| 11 |
Lorlatinib Versus Pemetrexed-Based Chemotherapy in Patients With ALK-rearranged NSCLC Previously Treated With Alectinib
|
Takeyasu, Yuki
|
|
|
3 |
5 |
p.
|
article
|
| 12 |
Overall Survival Benefits of First-Line Treatments for Asian Patients With Advanced EGFR-Mutated NSCLC Harboring L858R Mutation: A Systematic Review and Network Meta-Analysis
|
Chan, Sik-Kwan
|
|
|
3 |
5 |
p.
|
article
|
| 13 |
Presence of a Ground-Glass Opacity Component Is the True Prognostic Determinant in Clinical Stage I NSCLC
|
Hamada, Akira
|
|
|
3 |
5 |
p.
|
article
|
| 14 |
Real-World Perspectives From Surgeons and Oncologists on Resectability Definition and Multidisciplinary Team Discussion of Stage III NSCLC in People’s Republic of China, Hong Kong, and Macau: A Physician Survey
|
Lee, Victor Ho-Fun
|
|
|
3 |
5 |
p.
|
article
|
| 15 |
Revisiting Indications for Brain Imaging During the Clinical Staging Evaluation of Lung Cancer
|
Pichert, Matthew D.
|
|
|
3 |
5 |
p.
|
article
|
| 16 |
The Predictive and Prognostic Nature of Programmed Death-Ligand 1 in Malignant Pleural Mesothelioma: A Systematic Literature Review
|
Mansfield, Aaron S.
|
|
|
3 |
5 |
p.
|
article
|
| 17 |
TP53 Loss of Heterozygosity Induces De Novo SCLC Formation in EGFR-Mutated Lung Adenocarcinoma: A Case Report
|
Kunimasa, Kei
|
|
|
3 |
5 |
p.
|
article
|
Journal description